Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 399-412, September 2006

Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models

MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford, UK

INSERM U362, Institut Gustave Roussy, PR1, 39 rue Camille Desmoulins, 94805 Villejuif cedex, France

Myelofibrosis with myeloid metaplasia or idiopathic myelofibrosis is a myeloproliferative disease. It is known to be a stem-cell disorder that leads to a secondary and reactive stromal reaction in the bone marrow microenvironment that is responsible for impaired haematopoiesis. Although progress has been made in the elucidation of the pathogenesis of idiopathic myelofibrosis, lack of suitable models has limited our understanding of the pathology. The aim of this chapter is to address recent inferred new insights in mouse models into the pathogenesis of osteomyelofibrosis. These insights outline the role of transforming growth factor-β1 and osteoprotegerin in the promotion of myelofibrosis and osteosclerosis, respectively, paying special regard to the role of abnormal megakaryocyte proliferation and maturation.

Key words: animal models, emperipolesis, GATA-1 low, megakaryocytes, myelofibrosis, osteoprotegerin, osteosclerosis, thrombopoietin, transforming growth factor-β1

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The authors declare no financial interest or relationships concerning the work described herein.

PII: S1521-6926(05)00088-5

doi:10.1016/j.beha.2005.07.002

Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 399-412, September 2006